Showing 1151-1160 of 1395 results for "".
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Glaukos Receives FDA 510(k) Clearance of the iStent Infinitehttps://modernod.com/news/glaukos-receives-fda-510k-clearance-for-the-istent-infinite/2481013/Glaukos announced that it has received 510(k) clearance from the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is indicated for use in a standalone procedure to reduce elevated IOP in patients with primary open-angle glaucoma uncontrolled
- AbbVie and iSTAR Medical Announce Strategic Alliancehttps://modernod.com/news/abbvie-and-istar-medical-announce-strategic-alliance/2480980/AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal gives AbbVie the exclusive right to acquire iST
- iSTAR Medical Presents Positive Results for MINIject Across Three International Glaucoma Trialshttps://modernod.com/news/istar-medical-presents-positive-results-for-miniject-across-three-international-glaucoma-trials/2480908/iSTAR Medical presented 2-year safety and efficacy results in a meta-analysis of its STAR-I, STAR-II and STAR-III clinical trials for
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- iSTAR Medical Announces First MINIject Surgeries Performed in the UKhttps://modernod.com/news/istar-medical-announces-first-miniject-surgeries-performed-in-the-uk/2480727/iSTAR Medical announced that it has further expanded its commercial rollout for MINIject to the UK. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and currently the only commercially available supraciliary MIGS device. With this market exp
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- iSTAR Medical Receives European Market Approval for Glaucoma Implant MINIjecthttps://modernod.com/news/istar-medical-receives-european-market-approval-for-glaucoma-implant-miniject/2480460/iSTAR Medical
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinitehttps://modernod.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in p